Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.25    1.00 (7.55%)
Bid:
14.00
Ask:
14.50
Spread: 0.50 (3.571%)
Market Cap: £11.76m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

New Spin-out Company

8 Jun 2012 07:00

RNS Number : 9464E
Frontier IP Group plc
08 June 2012
 



 

AIM: FIPP

 

FRONTIER IP GROUP PLC

("Frontier IP" or "the Group")

 

First Spin-out Company

with

the University of Central Lancashire

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has agreed a collaboration with the University of Central Lancashire ("UCLan") to create and develop a new spin-out company from UCLan's Silicate Research Unit. The Group will provide advisory services and support in return for a 30% stake in the spin-out company and it is intended that Frontier IP will receive a share of licensing revenues.

 

The new spin-out company is being formed to license and commercialise the process which the Silicate Research Unit has developed to transform waste materials into a highly durable and functional material with applications in the construction industry. Waste materials that can be converted include ceramics, incinerated waste and lead glass. The new material has a wide range of uses including interior and exterior wall cladding, flooring, bricks and work surfaces and is also itself wholly recyclable. The Silicate Research Unit believes that the new material offers an attractive option for architects and designers, combining sustainability with the ability to customise the design and finish of the product. The product has recently been exhibited at a number of international design shows where it was well received.

 

UCLan is committed to delivering high impact research which has commercial potential. It has a well established research reputation within the areas of Business, Health, Humanities and Science which has lead to the emergence of specific research centres in a number of areas including Nuclear, and Nanotechnology and Bioengineering. In the latest Research Assessment Exercise*, all 17 of the subject areas UCLan submitted were rated as containing research of international excellence while 11 areas were assessed to be undertaking research which is world-leading.

 

Neil Crabb, Chairman of Frontier IP, said,

 

"This collaboration with the University of Central Lancashire represents an exciting new opportunity for Frontier IP. We have in-depth experience in commercialising university IP and we look forward to working with UCLan to maximise the potential of the Silicate Research Unit's cutting-edge product, which offers a 100% recyclable option to designers and architects across a broad range of applications."

 

Professor Margaret Bruce, Pro Vice Chancellor for Engagement at UCLan commented on the relationship,

 

"This is an important development for UCLan. By working together with our academics and Frontier IP, we will be able to capitalise on the excellent research within the university and bring innovative products to market."

 

David Binns from the Silicate Research Unit added,

 

"We are delighted that our innovative research is being taken out into the wider world. Our new products have the potential to make a real difference in the sustainable use of previously problematic waste materials."

 

 

* conducted jointly by the Higher Education Funding Council for England, the Scottish Funding Council, the Higher Education Funding Council for Wales and the Department for Employment and Learning, Northern Ireland and published in 2008

 

 

Enquiries

Company website: www.frontierip.co.uk

 

Frontier IP Group Plc

T: 0131 220 9491

Neil Crabb, Executive Chairman

Fairfax IS PLC

T: 020 7598 5368

(Nominated Adviser and Broker)

Stuart Gledhill / Katy Birkin

Biddicks

T: 020 3178 6378

Katie Tzouliadis / Sophie McNulty

 

 

 

Notes to Editor:

 

The University of Central Lancashire ("UCLan") offers over 500 undergraduate programmes and 180 postgraduate courses. The University has an established research reputation within the areas of Business, Health, Humanities and Science. In the Research Assessment Exercise 2008, all 17 subject areas submitted were rated as containing research of international excellence while 11 areas were assessed to be undertaking research which is world-leading. With approximately 32,000 students, the University indirectly contributes close to £250 million into the regional economy every year. UCLan is currently in the process of spending more than £120 million on new buildings and facilities to support teaching, learning and leisure activities.

 

Frontier IP Group Plc ("Frontier IP") specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGGVVNRGZZM
Date   Source Headline
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.